PF-Atlas › Clinical Trials › NCT05895565

A Multiple Ascending Doses Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects

PMG1015 · Phase 1

Registry ID

NCT05895565

Phase

Phase 1

Status

Completed

Drug / intervention

PMG1015

Sponsor

Pulmongene Ltd.

Start

2023-05-19

Enrollment

Locations

About this trial

This is a phase 1b randomized, double-blind, placebo-controlled, multiple ascending doses (MAD) study of PMG1015 in idiopathic pulmonary fibrosis (IPF) subjects. This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PMG1015 after MAD.

View NCT05895565 on ClinicalTrials.gov →

Explore related

All PMG1015 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT05895565 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.